Publications by authors named "Sorako Wakugawa"
Purpose: To evaluate the changes in choroidal thickness 1 year after half-dose photodynamic therapy (PDT) for central serous chorioretinopathy (CSC) using widefield swept-source optical coherence tomography.
Methods: We retrospectively reviewed 21 patients with CSC who unilaterally underwent half-dose PDT and completed a 12-month follow-up. Choroidal thickness was evaluated before and after PDT within an 18-mm circular grid centered on the fovea subdivided into nine areas in the treated and untreated fellow eyes.
This multicentre retrospective study evaluated the 1-year outcomes and safety profile of faricimab in treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Fifty-five patients (57 eyes) underwent loading therapy comprising three monthly faricimab injections. If dryness was achieved by the third month, subsequent treat-and-extend (TAE) follow-up continued at a minimum 8-week interval thereafter.
View Article and Find Full Text PDFPurpose: To evaluate the association between scleral thickness and a newly developed multimodal imaging-based classification of central serous chorioretinopathy (CSC).
Design: Retrospective, cross-sectional study.
Methods: This study included 217 eyes of 217 patients classified as simple or complex CSC based on the established protocols.
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol
January 2024
Purpose: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections.
Methods: This multicenter retrospective study examined nAMD eyes receiving monthly aflibercept injections switched to faricimab administered monthly up to 4 injections followed by injections at a minimum of 2-month intervals as per drug labeling. Data regarding age, sex, number of previous injections, treatment intervals, and best-corrected visual acuity (BCVA) were collected.
Article Synopsis
- * Researchers analyzed data from 115 patients, measuring various eye parameters using advanced imaging techniques, but found no significant differences in scleral thickness or other eye measurements between the affected and unaffected eyes.
- * The only notable difference was in the subfoveal choroidal thickness, which was thicker in the affected eyes, suggesting that choroidal thickening might contribute to CSC development, while scleral thickness remains unchanged.
This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan. We retrospectively reviewed 63 eyes of 61 patients with wAMD, including types 1, 2, and 3 macular neovascularization as well as polypoidal choroidal vasculopathy (PCV). Patients received three consecutive monthly intravitreal injections of faricimab as loading therapy.
View Article and Find Full Text PDFPurpose: To evaluate and compare the scleral thickness of patients with idiopathic central serous chorioretinopathy (iCSC) and steroid-induced central serous chorioretinopathy (sCSC) using anterior-segment OCT.
Design: Retrospective, comparative study.
Participants: One hundred ten eyes of 110 patients with central serous chorioretinopathy.
Purpose: To investigate the clinical and morphologic factors related to asymmetric dilated vortex veins in central serous chorioretinopathy (CSC).
Design: Retrospective, comparative study.
Participants: One hundred fifty-eight eyes of 158 patients with CSC.
Purpose: To investigate short-term treatment outcomes of intravitreal brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration (AMD) in a Japanese multicenter study.
Study Design: Retrospective case control study METHODS: The subjects were 58 eyes of 57 patients with neovascular AMD (43 men and 14 women, mean age 74.6 years) of whom 43 eyes of 42 patients completed initial loading of 3 monthly IVBr injections and were followed for more than 3 months.
Background/purpose: Observation of choroidal thickness after anti-vascular endothelial growth factor (VEGF) therapy may be important for the ideal management of neovascular age-related macular degeneration (AMD). This study investigated changes in subfoveal choroidal thickness (SCT) during loading doses of intravitreal injections of brolucizumab in eyes with neovascular AMD.
Methods: This study included 73 eyes of 72 patients with neovascular AMD at five university hospitals in Japan.
Purpose: To investigate the prevalence of ciliochoroidal effusion (CE) in central serous chorioretinopathy (CSC) using anterior-segment optical coherence tomography and its association with the clinical features of CSC.
Methods: Overall, 164 eyes of 164 patients with CSC and 51 eyes of 51 age- and sex-matched normal control participants were retrospectively examined. Anterior-segment optical coherence tomography was used to assess patients with CSC and control subjects for CE and scleral thickness.
Purpose: To elucidate clinical factors related to the presence of loculation of fluid (LOF) in the posterior choroid in central serous chorioretinopathy (CSC).
Design: Retrospective, cross-sectional study.
Methods: This single-center study included 158 eyes from 158 patients with CSC who were classified into LOF and non-LOF groups.
Purpose: To evaluate scleral thickness in central serous chorioretinopathy (CSC) using anterior segment (AS) OCT.
Design: Retrospective, comparative study.
Participants: Forty-seven eyes of 40 patients with CSC and 53 eyes of 47 age- and gender-matched normal control participants.